To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Oncolytics Enters into Sponsorship Agreement with NCIC CTG
Oncolytics Biotech Inc. has announced that it has entered into an agreement whereby the NCIC Clinical Trials Group (NCIC CTG) at Queen's University in Kingston, Ontario, will sponsor and conduct a randomized Phase II study of REOLYSIN® in patients with advanced or metastatic breast cancer.
"We are excited to announce our fourth randomized study with the NCIC CTG," said Dr. Brad Thompson, President and CEO of Oncolytics. "This study will build upon pre-clinical research conducted with REOLYSIN in human breast cancer primary tumour samples."
The study will be an open-label, randomized, non-blinded, Phase II clinical study of REOLYSIN given in combination with paclitaxel versus paclitaxel alone.
Approximately 50 response-evaluable patients will be enrolled in each arm, after a six- to nine-patient safety run-in.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
